CUAMC
TCRX icon

China Universal Asset Management Company’s TScan Therapeutics TCRX Stock Holding History

China Universal Asset Management Company’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9,197
Closed -$16.7K – 530
2025
Q3 		$16.7K Sell
9,197
-1,310
-12% -$2.32K ﹤0.01% 463
2025
Q2 		$15.2K Buy
10,507
+660
+7% +$954 ﹤0.01% 455
2025
Q1 		$13.6K Sell
9,847
-563
-5% -$1.22K ﹤0.01% 467
2024
Q4 		$31.6K Buy
+10,410
New +$47.2K ﹤0.01% 474

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $508M AUM 163.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

China Universal Asset Management Company's TCRX Position: Q4 2025 in Review

China Universal Asset Management Company sold out of TScan Therapeutics (TCRX) in Q4 2025, closing a stake of 9,197 shares — an estimated $16.7K sold.

China Universal Asset Management Company first reported a position in TCRX in Q4 2024 and held it in 4 quarters. The position peaked at $31.6K in Q4 2024. 61 funds tracked by Wall St. Rank hold TCRX as of Q4 2025.

  • China Universal Asset Management Company reported no remaining TScan Therapeutics position as of Q4 2025 after selling out during the quarter.
  • China Universal Asset Management Company sold 9,197 TScan Therapeutics shares in Q4 2025, an estimated $16.7K.
  • China Universal Asset Management Company first reported a position in TScan Therapeutics in Q4 2024 and held it in 4 quarters.
  • China Universal Asset Management Company's TScan Therapeutics position peaked at $31.6K in Q4 2024.
  • 61 funds tracked by Wall St. Rank held TScan Therapeutics as of Q4 2025.

Based on China Universal Asset Management Company's 13F filing for Q4 2025, filed 29 Jan 2026.